Therapeutic Targeting of FLT3 gate keeper mutation with E2082-0047 in traditional and a novel Immunocompetent murine adoptive transfer model of AML

Written By Guest User
Guest User
Previous

A novel Selective BCL2 inhibitor with limited immune suppression and improved safety compared to venetoclax
Next

ASH2022: A Novel Inhibitor of FLT3 and its Drug-resistant Mutants with Superior Activity to Gilteritinib in MOLM-13 Preclinical Acute Myeloid Leukemia Xenograft Model